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Abstract (250 word limit) 
Introduction: Approaches to economic evaluations of stroke therapies are varied and 
inconsistently described. An objective of the European Stroke Organisation (ESO) Health 
Economics Working Group is to standardise and improve the economic evaluations of 
interventions for stroke. 
Methods:  
The ESO Health Economics Working Group and additional experts were contacted to 
develop a protocol and a guidance document for data collection for economic evaluations of 
stroke therapies. A modified Delphi approach, including a survey and consensus processes, 
was used to agree on content. We also asked the participants about resources that could be 
shared to improve economic evaluations of interventions for stroke. 
Results: Of 28 experts invited, 16 (57%) completed the initial survey, with representation 
from universities, government, and industry. More than half of the survey respondents 
endorsed 13 specific items to include in a standard resource use questionnaire. Preferred 
functional/quality of life outcome measures to use for economic evaluations were the 
modified Rankin Scale (14 respondents, 88%) and the EQ-5D instrument (11 respondents, 
69%). Of the 12 respondents who had access to data used in economic evaluations, 10 (83%) 
indicated a willingness to share data. A protocol template and a guidance document for data 
collection were developed and are presented in this manuscript. 
Conclusion: The protocol template and guidance document for data collection will support a 
more standardised and transparent approach for economic evaluations of stroke care.  
 
Key words: stroke, economic evaluation, health policy, health outcomes, modified Rankin 
Scale, EuroQol  
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Introduction 
Interventions for stroke need to be evaluated for their cost-effectiveness, as well as their clinical 
effectiveness. Several countries now incorporate results of health-economic analyses as part of 
their national clinical guidelines for stroke.1, 2 A paucity of published cost-effectiveness studies 
means that very few clinical recommendations in these guidelines have information about the 
value of treatments. Comparability and translation of economic evaluation results are 
complicated by variability of study methods and differences in health care system organization 
and expenditure across national and regional settings.3 Another limitation is that the quality of 
studies varies between studies.4 Therefore, with the growing number of interventions becoming 
available to prevent or treat stroke, it is important to standardise and improve the methods for 
conducting cost-effectiveness studies in stroke. 
 
While checklists exist for the reporting of economic evaluations, no guidance is provided 
regarding collection of data on resource use or costs. In addition, existing recommendations 
for health-related economic evaluations are generic and do not provide guidance specifically 
for research related to patients with stroke. The European Stroke Organisation (ESO) Health 
Economics Working Group had its first meeting in 2015 to discuss the standardisation of health 
economic methods for future clinical trials,3 and was formally established in 2016 with broad 
aims of compiling and developing resources to facilitate economic evaluations of stroke 
therapies (Table 1). In this manuscript, we give recommendations for a more standardised and 
transparent method for economic evaluations of stroke care. 
 
Methods 
The ESO Health Economics Working Group was established in 2015 after discussion among 
53 ESO members who had experience with economic evaluations of stroke therapies. Of the 
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53 experts, 10 were nominated as members of the executive group, while a further 14 were 
retained as corresponding members.  
 
The working group used a modified Delphi technique for the present project.5 At the annual 
meeting at the ESO Conference in Prague in 2017, the participants agreed on a survey, which 
was distributed to 28 experts in economic evaluations of stroke therapies, including the 
members of the ESO Health Economics Working Group. The core questions in the survey 
focused on protocols for economic evaluations and the data collected for economic evaluations 
(see Online Supplement). The survey also included questions about resources that could be 
shared to improve economic evaluations in stroke research, including access to existing 
datasets and models used for economic evaluations. 
 
Based on the responses from the survey, a protocol template and a guidance document for data 
collection were developed. These materials were further refined prior to presentation at the 
annual meeting at the ESO Conference in Gothenburg in 2018, where the materials were 
reviewed and consensus on the content was reached by the working group. 
 
Results 
The survey was sent to the 26 working group members and two other researchers nominated 
by the working group for their specific expertise. Of the 28 people invited to participate in the 
survey, 16 responded, of which seven worked at universities or hospitals, two in government, 
two in industry and five did not provide their affiliations or occupation.  
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Use of standard protocols 
Of the 16 respondents, 13 did not use a standard template for economic evaluation protocols 
(81%). However, five (31%) used a checklist to guide the development of their protocols. 
Respondents used the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS),6 the Drummond checklist7 and the National Institute for Health and Care 
Excellence (NICE) guidelines for England to guide development of protocols.8 The protocol 
items suggested by the respondents are outlined in Figure 1.  
 
Use of questionnaires to capture resource use 
Fifteen respondents did not have a standard resource use questionnaire for economic 
evaluations (94%). Respondents indicated their support for items to be included in a standard 
questionnaire to capture resource use (Figure 2). At least 50% of respondents supported 
inclusion of 13 suggested items for a standard resource use questionnaire. Other suggested 
items compiled from the open text responses were: outpatient procedures, diagnostic tests, 
transport between hospitals, distance to care provider, and income. When asked about the level 
of detail required for the data collected, it was suggested that when collecting information about 
consultations/services provided by health professionals, the number of consultations, type of 
provider, duration, and out-of-pocket costs were important. When collecting information about 
medications, it was suggested that researchers could collect the broader categories of 
medications used by patients (e.g. antihypertensive, antithrombotic). The importance of 
tailoring the data collection was emphasised, and it was suggested that the amount of detail 
collected should depend on whatever helps to quantify the important drivers of cost relevant to 
that study.  
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Estimating resource use from routinely collected data 
The majority of respondents indicated that they estimated resource use based on stroke type 
(n=11, 69%), discharge destination (n=10, 63%) or by first ever or recurrent stroke (n=9, 56%). 
Other clinical or demographic data that could be used to estimate resource use included time 
since stroke, modified Rankin Scale9 (mRS) at discharge and 90 days, age, sex, comorbidities 
(e.g. atrial fibrillation) and the National Institute of Health Stroke Scale10 (NIHSS) score. 
 
Patient outcomes  
The most popular outcome measure for economic evaluations of stroke therapies were the 
mRS9, 11 (n=14, 88%) followed by the EQ-5D instrument12 (n=11, 69%). Other outcome 
measures included the Stroke Impact Scale,13 Assessment of Quality of Life14 (AQoL) and the 
Barthel Index.15, 16 All respondents indicated that they collected the mRS as an ordinal scale. 
An advantage of the mRS was having published literature on the direct costs for each category 
which is useful for studies where it has not been possible to collect data on resource 
utilisation/costs directly from participants. An advantage of health-related quality of life 
measures, like the EQ-5D and the AQoL, is that they can generate utility values that can directly 
enter into calculations of quality-adjusted life years (QALYs). The mRS and Barthel Index can 
be converted to utility values to serve this purpose, although the assigned utility scores are less 
granular than with direct quality of life measures.17, 18 
 
Sharing available resources and data for economic evaluations 
There were 11 respondents (69%) who indicated that they had access to datasets used for 
economic evaluations. The scope of data was broad and included data from clinical trials 
(acute, subacute and community-based intervention studies), administrative data, national 
registry data or cost data.  
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Of the 11 respondents who had access to existing economic evaluations data, 9 (82%) replied 
that they were willing to share data and 9 (90%, 1 missing response) indicated that permission 
to use the data would be needed, as well as funding to cover any administrative expenses (e.g. 
formatting the data). The issue of needing ethical approvals for secondary use of the data and 
the importance of acknowledging the original source of the data was expressed.  
 
Models for economic evaluations  
The short duration of clinical trials and the long term consequences of stroke renders modelling 
almost inevitable since economic evaluations based upon trial results would not capture fully 
the benefits or harms of interventions. Eight of the respondents (50%) indicated that they had 
previously used models for economic evaluations, including Markov models, partition survival 
modelling and discrete event simulation. Several were developed in Microsoft Excel with and 
without add-on software and with different levels of sophistication (Visual Basic for 
Applications coding). The use of software such as TreeAge, SAS, R and Stata for developing 
models was also mentioned. 
 
Final protocol template and guidance document for collecting resource use and cost data 
Table 2 includes the items that were agreed for a protocol template for economic evaluations 
of stroke therapies, and Table 3 includes information to guide data collection on resource use. 
In Table 3 we highlight the importance of estimating the additional costs of the intervention, 
which would include items such as the cost of therapists and support staff, training and 
education, equipment, medication or facility costs. Estimating the costs of the intervention may 
be complex, and this must be considered in the data collection. For example, the costs of a 
novel treatment with a large capital outlay may be more obvious than subtle adaptations to 
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existing care pathways. It was noted that evidence from process evaluations would assist with 
informing the costs to include.  
 
 
Discussion 
In this article, we have presented a consensus-based protocol template and a guidance 
document for the collection of resource use data that can be used for economic evaluations of 
stroke therapies internationally. We recommend using these tools in addition to the generic 
guidelines for conducting and reporting economic evaluations. To support use in practice, two 
examples of economic evaluations of stroke therapies that have been summarised using our 
protocol template have been provided in the online supplement and Supplemental Table I.  
 
In addition to the resources we have developed to improve the quality of economic evaluations 
of stroke interventions, participants supported the collection of information that will enable 
comparison of studies. Providing information on case mix and stroke severity of participants 
(e.g. the National Institute of Health Stroke Scale scores) would also assist with comparison 
between economic evaluations. Researchers should also consider reporting information on the 
structure of healthcare systems and hospitals, particularly for multi-country studies. In 
intensive care studies, the Therapeutic Intervention Scoring System (e.g. TISS-28) is 
recommended as a way to standardise costs between countries.19 A similar tool for stroke care 
could be developed for stroke as an extension of our current work. In the A Very Early 
Rehabilitation Trial (AVERT), the data collection instruments were tailored to different study 
centres in Australia, Asia and the United Kingdom.20 Reporting cost base years, currencies, 
inflation indices/rates and currency exchange indices/rates is recommended in generic 
guidelines for reporting economic evaluations. Adhering to this recommendation would permit 
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researchers to assess the comparability and generalisability of economic evaluations across 
settings.  
 
Standardising the time horizons and perspectives would also assist with comparison of results. 
When conducting studies using long-term time horizons, results for shorter-term time horizons 
could also be reported. The perspectives of studies are often limited to direct inpatient costs 
(hospital or rehabilitation) although post-hospital healthcare (community) and societal costs 
(broader than just the health sector impacts) are as important. The costs of long-term care and 
support are also important, especially in evaluations of interventions that affect disability after 
stroke. For example, early after stroke, hospitalisation and rehabilitation would be considered 
as essential since these are major contributors to costs in the first year after stroke.21, 22 In the 
longer-term, there is evidence that residential aged care facilities and informal care comprise 
the majority of costs.23, 24 Therefore, we recommend researchers report the type of costs 
incurred (e.g. hospital, community health services, gains/losses to productivity) and the time 
point at which these costs were incurred. For longer term economic evaluations societal costs 
must be captured to have meaningful results. Effects on household productivity (e.g. cooking, 
cleaning, gardening and caring for family members) may also be considerable in older cohorts 
or for women,25 but this is typically overlooked in health technology assessments. Reporting 
informal care quantities, valuation approaches and costs are recommended to enable alternative 
valuations to be estimated if necessary. In other fields, questionnaires that can be used to collect 
indirect costs (carers’ time and indirect consequences on carers’ health) have been validated.26 
 
Participants acknowledged that a comprehensive economic evaluation may require multiple 
overlapping data collection methods to be used. This could include direct measurement of 
healthcare resource use from registries or hospital billing systems to allow for standardised 
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capture of all given care, a detailed evaluation of workforce time spent with the patient to add 
accuracy to measuring a specific care component, and the administration of patient/caregiver 
questionnaires to collect data on informal care, lost productivity and any health or social care 
resource use (societal costs) which is not accessible from routine records. The possibility of 
data linkage for the purposes of economic evaluations should be explored given there are 
inaccuracies with self-reported data and the potential for recall bias especially when there are 
long delays in between follow-up assessments.22 Ideally, data collected to estimate costs should 
be traceable to routinely collected information in registries and administrative databases. 
Information about resource use prior to stroke can also be obtained through data linkage in 
order to quantify stroke-specific costs (i.e. increase in resource use after stroke). In addition, 
data linkages with clinical quality registries can make it possible to obtain patient reported 
outcomes at routine follow-up assessments. For example, by linking to the Australian Stroke 
Clinical Registry mRS and health-related quality of life using the EuroQol-5 dimension-3 level 
questionnaire collected at 90 and 180 days after stroke would be available.27 However, the time 
delays in obtaining linked data and their complexity to analyse needs careful consideration 
when planning studies.28 
 
The participants recognised the potential value of having data repositories or directories of data 
custodians and existing protocols, datasets, questionnaires and models that might be shared and 
adapted. Once available, having access to these resources will expedite economic evaluations 
of stroke therapies and facilitate comparability between studies. Processes to seek permission 
to access these resources, in compliance with relevant information governance legislation and 
frameworks, remain to be developed. However, improved accessibility is likely to emerge over 
time from wider movements towards open access to research data.  
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Our process for achieving the outcomes of this work in seeking to improve economic 
evaluations undertaken within the field of stroke may be an exemplar for other speciality fields 
within health. We acknowledge that in the final review we took a pragmatic approach to finalise 
the outstanding decisions within the executive committee, and this may be considered a 
limitation of the consensus process. 
 
Summary 
The ESO Health Economic Working Group aims to standardise and improve the methods of 
health-economic evaluations of stroke therapies. The resources that were developed and 
presented in this paper will facilitate these aims and ultimately contribute to the development 
of evidence-based clinical guidelines to improve patient care.  
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Table 1. Actions suggested for the working group 
Compiling existing resources for economic evaluation 
1. Develop a directory of health-economic models, protocols and questionnaires 
2. Investigate processes required to identify and share such resources  
3. Identify manuals for health technology assessment in each country 
Development of resources for the standardisation of economic evaluations 
1. Develop a protocol template for health-economic evaluations in stroke  
2. Develop a common model 
3. Develop a data collection questionnaire template with recommendations for essential, 
recommended and elective categories of variables  
4. Develop recommendations on how data should be systematically collected 
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Table 2. Protocol template 
Item Detail required or examples 
Population and setting Country/region 
Sub-groups of patients with stroke 
Organisational structure (private/public)  
Care pathways 
Research question E.g. to determine/estimate the cost-effectiveness of intervention 
compared to comparator/control group 
 
Outcomes 
 
The outcome that is used for the cost-effectiveness measure 
Questionnaire used to estimate quality of life 
Treatment groups 
 
Intervention groups 
Comparator/control groups 
 
Perspective Health service 
Patient 
Societal 
Direct/indirect 
 
Study design / data source Alongside RCT 
Model-based economic evaluations using data from multiple sources 
Economic study design Cost benefit 
Cost effectiveness 
Cost utility 
Budget impact analysis 
 
Economic model E.g. model assumptions, model name and reference in literature 
 
Reference year E.g. Year and inflation/deflation. Source for adjusting costs 
 
Time horizon Assumptions made for modelling longer-term costs and outcomes 
 
Discounting Nationally recommended – usually 3% or 5% 
Resource use collected E.g. Hospital readmissions, family physician contacts 
 Delivery of the intervention and justification for inclusion 
 If used, the method of estimating resource use based on clinical or 
demographic details of participants and the reference in literature 
 
Data collection methods Administrative data 
Patient self-report via survey 
 
Sub-group analysis Stroke type 
Hospital type (private/public) 
 
Sensitivity analysis Monte Carlo simulation (multivariable) 
One-way sensitivity 
Scenario analysis 
 
Funder Government 
Industry 
Private insurance 
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Table 3. Resource use data collection guidance 
Variables Data collection guidance 
Additional costs of treatment This should be the costs of delivering the new treatment that are above and beyond a comparator treatment or usual care 
Data collection to be considered for studies using a health care sector perspective* 
Transport Transport between hospital (e.g. transfer to a centre providing reperfusion) or from home, type of vehicle 
Rehabilitation Inpatient or outpatient rehabilitation, number of sessions, length of stay, specific services and procedures provided while in 
rehabilitation (e.g. assessment of impairment) 
Hospital presentations Number of presentations, type of presentation (e.g. emergency department or admission), dates or length of stay, specific 
services and procedures provided while in hospital (e.g. reperfusion) 
Respite care Number of times used, length of stay 
Medications Type of medications (e.g. antihypertensive medications), number of medications, dose, time on medication 
Change in residence and living 
arrangements 
Information to capture changes in residence as this is an indicator of independence that affects costs (e.g. costs of moving to 
an aged care facility may be applied) 
Home modifications Type of home modifications and out-of-pocket costs (e.g. for the installation of ramp to home) 
Aids and equipment Type of aids and equipment and out-of-pocket costs (e.g. for a walking frame) 
Community services Type of service, number of times provided and out-of-pocket costs 
Family physician contacts Number of contacts, other associated services (e.g. practice nurse) and out-of-pocket costs 
Specialist contacts Type of specialist, number of contacts and out-of-pocket costs 
Private therapy Type of therapy, number of contacts and out-of-pocket costs 
Diagnostic tests Type of tests, number of tests and out-of-pocket costs 
Data collection to be considered for studies using a societal perspective 
Employment/volunteer work Type of work and hours, income and change since stroke 
Carer employment/volunteer work Type of work and hours, income and change since stroke 
Household productivity Type of activity and hours and change since stroke (e.g. cleaning, cooking, gardening, caring for family members) 
Leisure time Type of activity and hours and change since stroke 
Additional items to consider 
Clinical assessments at baseline These should be clinical assessments that can be used to estimate costs (e.g. modified Rankin Scale) 
Clinical outcomes after treatment These should be clinical assessments that can be used to estimate costs (e.g. modified Rankin Scale) 
* Collecting data on the utilisation of health services can be labour intensive. Limiting data collection to certain categories of resource use and types of resources 
should be justified. 
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Figure 1. Support for the inclusion of items in a standard health-economic evaluation 
protocol in stroke 
 
 
Figure 2. Support for the inclusion of suggested items on a standard resource use 
questionnaire in stroke 
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ESO HEWG Survey Questions 
 
PROTOCOLS 
1) Do you have a standard protocol for economic evaluations? 
[Yes / No] 
 
If yes, - 1b) Would you be willing to share your protocol or summary of a protocol? 
[Yes / No] 
 1c) Would others need permission to use it? 
[Yes / No] 
[free text] 
 
2) Indicate standard headings that you believe should be included in an economic 
protocol 
[Tickboxes] 
 Population 
 Research question 
 Primary and secondary outcomes 
 Treatment groups  
 Perspective (E.g. societal, health-care system) 
 Study design (E.g. parallel to RCT, simulation model) 
 Economic study design (E.g. cost-utility analysis) 
 Economic model 
 Reference year 
 Time horizon 
 Discounting 
 Costs collected 
 Data collection methods 
 Subgroup analysis 
 Sensitivity analysis 
 Funder 
 
3) What other information should be provided in a protocol for an economic 
evaluation? 
[free text] 
 
4) Is the information you provide on a protocol guided by a checklist or framework?  
[Yes / No] 
 
If yes, - 4b) State the checklist or framework 
[free text]  
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RESOURCE USE DATA 
5) Do you have a standard resource-use questionnaire for economic evaluations? 
[Yes / No] 
 
If yes, - 5b) Would you be willing to share the standard resource-use questionnaire 
template? 
[Yes / No] 
 5c) Would others need permission to use it? 
[Yes / No] 
[free text] 
 
6) What do you think are important data that should be captured on a standard 
resource use questionnaire? 
[Tickboxes] 
 Place of residence 
 Change in living arrangements 
 Hospital presentations 
 Rehabilitation (inpatient/outpatient) 
 Family physician contacts 
 Specialist contacts 
 Private therapy 
 Community services 
 Aids and equipment 
 Home modifications 
 Respite care 
 Employment/volunteer work 
 Carer employment/volunteer work 
 Medications 
 
7) What other resource-use information should be captured on a resource use 
questionnaire? 
[free text] 
 
8) What level of detail is captured for these items on the resource use questionnaire 
(E.g. number of contacts, duration of contacts, out-of-pocket costs)?  
[free text] 
 
9) Are there routinely collected clinical/demographic data that should be used to 
estimate resource use? 
[Tickboxes] 
 First ever or recurrent stroke 
 Stroke type 
 Discharge destination 
 
10) What other routinely collected clinical/demographic data should be collected for 
estimating resource use? 
[free text] 
 
 
Online Supplement  
PATIENT-REPORTED OUTCOME MEASURES  
11) Which patient reported outcome measures do you collect for economic evaluations? 
 SIS 
 Modified Rankin Scale 
 EQ-5D-3L 
 AQoL 
 Other (please specify) 
 
12) If you collect the modified Rankin Scale, is it collected as an ordinal scale? 
[Yes / No] 
 
EXISTING DATASETS 
13) Have you collected or do you have access to any data used in economic evaluations 
(e.g. patient-level cost data)? 
[Yes / No] 
 
If yes,  
14) Please describe the dataset:  
[free text responses] 
 
15) What was the purpose of the data when originally collected? 
[free text] 
 
If yes, - 15b) Would you be willing to share the data? 
[Yes / No] 
 15c) Would others need permission to use it? 
[Yes / No] 
16) What is the perspective of the data collected? 
 Hospital/health service 
 Government 
 Societal 
 Private 
 Patient 
 
17) What is the structure and format of the data (e.g. Microsoft Excel)? 
[free text] 
 
18) Please provide any publications where the data are reported 
[free text] 
 
ECONOMIC MODELLING 
19) Have you used modelling for economic evaluations? 
[Yes / No] 
 
20) What kind of model and what software was used for the creation of this model? 
[free text] 
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HEALTH TECHNOLOGY ASSESSMENT 
21) Does your country have specific costing guidelines for health technology assessment 
or other purposes?  
[Yes / No] 
If yes,  
22) Please provide a reference or URL 
 
STROKE GUIDELINES 
23) Does the stroke clinical guideline in your country include information about 
economic evaluations supporting the recommendations? 
[Yes / No] 
 
If yes,  
24) How is this incorporated in the guidelines? 
 
25) Please provide a reference or URL 
 
26) Please provide any other general comments regarding the survey 
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Detailed methods and timeline for establishing agreement on a protocol template and 
guidance document for data collection 
We used a modified Delphi technique which is a method for consensus-building with a group 
of experts whereby an initial questionnaire is used as the basis for obtaining responses which 
are then summarised and fed back to participants.1 The most important first step is choosing 
appropriate participants because this directly relates to the quality of the results generated.1 The 
ESO Health Economics Working Group was established via a process of identifying experts or 
their nominees associated with the ESO who were publishing relevant papers, including 
industry. An initial group of 53 experts were identified to be potential members of the working 
group and 10 agreed to be Executive members of the working group (DAC nominated as Chair), 
while a further 14 were retained as corresponding members. JK and AW were included in the 
working group as coordinators. The Executive committee was responsible for driving the work 
program including for this project. 
 
The following process was undertaken to achieve consensus for a protocol template and a 
guidance document for data collection that could be used to improve the standard of economic 
evaluations of stroke interventions. Proposed questions for a survey were developed by DAC, 
JK and AW and presented to 20 members of the working group at the annual meeting at the 
European Stroke Conference 2017 held in Prague (17/05/2017). Proposed questions were 
refined into a survey by DAC, JK and AW via email discussions (21/05/2017) and distributed 
to 26 members of the working group on 11/07/2017. The core questions in the survey focused 
on protocols for economic evaluations and the data collected for economic evaluations 
(resource use items included in questionnaires and patient-reported outcome measures) (see 
Online Supplement). The survey also included questions about resources that could be useful 
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to improve economic evaluations of stroke therapies, including access to existing datasets and 
models used for economic evaluations. 
 
The survey was closed on 16/08/2017 after recipients were given a final reminder on 
02/08/2017. Initial survey results were analysed by JK and presented to DAC and AW via 
email correspondence and a teleconference (09/11/2017). The results of the survey were then 
discussed during a teleconference with available Executive working group members (n=8) on 
27/11/2017. A protocol template and guidance document for data collection were developed 
based on the survey results. These materials were further refined based on the feedback from 
the working group by DC and JK and discussed via email (08/04/2018) and a teleconference 
(24/04/2018) with AW prior to presentation at the annual face to face meeting at the European 
Stroke Conference 2018 held in Gothenburg, 16/05/2018. The meeting was attended by 9 
members of the working group. The draft materials were reviewed, and consensus reached. It 
was agreed that a manuscript would be prepared as a method for ensuring all working group 
members contributed to the final scope and presentation of the protocol template and guidance 
document. 
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Protocol summaries of case studies  
The Very Early Rehabilitation of Speech (VERSE) trial2 used standardised questionnaires to 
collect resource use, and validated questionnaires to collect information on outcomes at routine 
follow-up assessments conducted at 12 and 26 weeks after stroke. The resource use data 
collected will enable an economic evaluation from both a societal and health sector perspective 
at a time horizon of 26 weeks. When there is an absence of data obtained directly from 
participants and/or the healthcare system, simulation modelling using a range of ‘best available’ 
data may be required. In the economic evaluation  by Sandercock et al.,3 a decision analytic 
model was used to determine the cos-utility of thrombolytic treatment for acute ischaemic 
stroke from the perspective of the United Kingdom’s National Health Service at a 1-year and 
a lifetime time horizon. Markov modelling was used after the first year. The patient population 
was based on data obtained for a stroke registry, effectiveness estimates of thrombolysis were 
taken from a Cochrane systematic review, utility values for each health state were obtained 
from published literature, and costs were obtained from health services in the United Kingdom 
and from published literature.  
 
Supplemental table I Case study examples 
 A Very Early Rehabilitation in Speech 
(VERSE) Trial 
Sandercock et al, 2004 
Population 
and setting 
Patients with acute stroke and aphasia at 
acute care hospitals and accompanying 
rehabilitation services throughout 
Australia 
 
Acute stroke patients admitted to hospital 
from the Lothian Stroke Register in 
England 
 
Research 
question 
To determine the cost-effectiveness of an 
intensive prescribed aphasia therapy 
compared to non-prescribed and non-
intensive aphasia therapy 
To estimate the cost-effectiveness of 
thrombolytic treatment in the UK 
National Health Service 
 
Outcomes Cost per 4.4% improvement on the 
aphasia quotient 
 
Cost per quality adjusted life year gained 
Estimates of quality adjusted life years 
gained were obtained directly from 
patients in the Lothian Stroke Register 
Treatment 
groups 
 
 Intensive prescribed aphasia 
therapy (VERSE) 
 Standard care 
 Standard care plus thrombolysis 
  
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 Non-prescribed, intensive aphasia 
therapy (usual care-plus) 
 Non-intensive usual care aphasia 
therapy (usual care) 
Perspective Societal with the main focus on the health 
sector, including out-of-pocket costs and 
productivity 
 
Broad health care and personal social 
services perspective 
 
Study 
design / 
data source 
Resource use collected from a randomised 
controlled trial 
 
Decision analysis model (until 1 year time 
horizon) and a Markov modelling 
approach (lifetime time horizon) using 
published literature and data collected 
from the Lothian Stroke Register.  
 Published literature and data on 
treatment and outcomes from the 
Lothian Stroke Register,  
 Published literature for 
effectiveness estimates of 
thrombolysis and outcomes 
 Unit cost information obtained 
from health services 
 
Economic 
study 
design 
Cost-effectiveness 
 
Cost utility 
 
Economic 
model 
N/A 
 
Original decision analysis model, but 
costs of rehabilitation and long-term care 
obtained from the MEDTAP model. 
 
Reference 
year 
2017, with adjustments between years 
made using the Total Health Price Index 
published by the Australian Institute of 
Health and Welfare 
 
Not stated 
 
Time 
horizon 
26 weeks 
 
1 year and lifetime 
 
Discounting N/A 
 
6% 
 
Resource 
use 
collected 
 Hospital presentations 
(emergency department 
presentation and hospital 
admissions) 
 Rehabilitation (inpatient and 
outpatient) 
 Residential aged care 
 Ambulance transfers 
 GP services 
 Rehabilitation services provided 
at home 
 Community services 
 Speech aids and equipment 
 Private speech therapy sessions 
 Respite care 
 Employment 
 Informal care provided 
 Therapist time 
 Thrombolysis drug costs 
 Length of stay in hospital 
 Rehabilitation 
 Long-term care 
  
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Data 
collection 
methods 
Standardised resource use questionnaire 
administered at 12 weeks and 26 weeks 
 
From published sources 
 
Sub-group 
analysis 
No 
 
No 
 
Sensitivity 
analysis 
Monte Carlo simulation 
 
 One-way sensitivity analysis 
 Threshold analyses 
 Monte Carlo simulation 
 
Funder National Health and Medical Research 
Council 
 
National Health Service 
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